P051 Rollout of Kaftrio® to adult cystic fibrosis patients at the Royal Brompton Hospital during a global pandemic
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Cystic Fibrosis"
DOI: 10.1016/s1569-1993(21)01078-x
Abstract: Objectives: To review the rollout process for Kaftrio® at this large adult CF Centre following approval by the European Medicines Agency (EMA) in June 2020, EMA marketing authorisation and commissioning by NHS England on 21st… read more here.
Keywords: access; adult; cystic fibrosis; rollout ... See more keywords
P20 Does Kaftrio® reduce IV antibiotic burden in cystic fibrosis? A retrospective observational evaluation
Sign Up to like & getrecommendations! Published in 2023 at "Archives of Disease in Childhood"
DOI: 10.1136/archdischild-2023-nppg.19
Abstract: Aim Respiratory failure remains the most common cause of death in Cystic Fibrosis (CF) with chronic/complex infection a significant contributory factor. Infection frequency and associated treatment burden increase the risk drug-resistant organisms; however, stewardship strategies… read more here.
Keywords: kaftrio; evaluation; antibiotic burden; cystic fibrosis ... See more keywords
P28 An audit of liver function testing in paediatric patients newly started on Kaftrio®
Sign Up to like & getrecommendations! Published in 2023 at "Archives of Disease in Childhood"
DOI: 10.1136/archdischild-2023-nppg.27
Abstract: Aim To investigate whether the current practice of liver function test (LFT) monitoring within a large tertiary paediatric cystic fibrosis centre adheres to local and national guidelines with respect to baseline monitoring, frequency of monitoring… read more here.
Keywords: liver function; kaftrio; treatment; year ... See more keywords